HC Wainwright Forecasts Arvinas’ Q1 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Arvinas in a note issued to investors on Thursday, November 6th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.70) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. HC Wainwright also issued estimates for Arvinas’ Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.74) EPS and Q4 2026 earnings at ($0.71) EPS.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.27. Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.The firm had revenue of $41.90 million during the quarter, compared to the consensus estimate of $29.36 million. During the same quarter in the previous year, the company posted ($0.68) earnings per share. The company’s quarterly revenue was down 59.1% on a year-over-year basis.

Several other research firms also recently weighed in on ARVN. The Goldman Sachs Group restated a “sell” rating and set a $6.00 price objective (down previously from $8.00) on shares of Arvinas in a report on Wednesday, October 15th. Wells Fargo & Company dropped their price target on shares of Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday. Bank of America lowered Arvinas from a “buy” rating to a “neutral” rating and set a $10.00 price objective for the company. in a report on Wednesday, September 24th. Barclays raised their target price on Arvinas from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Arvinas in a report on Wednesday, October 8th. Eleven research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $16.34.

Arvinas Stock Up 6.3%

Shares of ARVN opened at $10.63 on Friday. The business’s fifty day moving average is $8.83 and its 200 day moving average is $7.92. Arvinas has a 12-month low of $5.90 and a 12-month high of $28.70. The stock has a market cap of $682.66 million, a P/E ratio of -13.12 and a beta of 2.38.

Institutional Investors Weigh In On Arvinas

Hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd lifted its stake in Arvinas by 965.4% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company’s stock worth $33,000 after purchasing an additional 4,219 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Arvinas by 491.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after purchasing an additional 4,835 shares during the period. Canada Pension Plan Investment Board raised its position in shares of Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after buying an additional 3,500 shares in the last quarter. CWM LLC boosted its stake in Arvinas by 2,317.5% during the first quarter. CWM LLC now owns 7,615 shares of the company’s stock valued at $53,000 after buying an additional 7,300 shares during the period. Finally, State of Wyoming purchased a new position in Arvinas during the third quarter worth about $68,000. 95.19% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Arvinas news, Director Briggs Morrison bought 30,000 shares of the business’s stock in a transaction on Monday, September 22nd. The stock was purchased at an average price of $7.57 per share, for a total transaction of $227,100.00. Following the completion of the transaction, the director directly owned 76,021 shares of the company’s stock, valued at $575,478.97. This trade represents a 65.19% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.73% of the company’s stock.

Arvinas announced that its board has authorized a stock repurchase plan on Wednesday, September 17th that allows the company to repurchase $100.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 17.9% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.